Uptake of ethanolamine in neuronal and glial cell cultures

Choline transporter-like proteins 1 and 2 are newly identified plasma membrane and mitochondrial ethanolamine transporters

The membrane phospholipids phosphatidylcholine and phosphatidylethanolamine (PE) are synthesized de novo by the CDP-choline and CDP-ethanolamine (Kennedy) pathway, in which the extracellular substrates choline and ethanolamine are transported into the cell, phosphorylated, and coupled with diacylglycerol to form the final phospholipid product. Although multiple transport systems have been established for choline, ethanolamine transport is poorly characterized and there is no single protein assigned a transport function for ethanolamine. The solute carriers 44A (SLC44A) known as choline transporter-like proteins-1 and -2 (CTL1 and CTL2) are choline transporter at the plasma membrane and mitochondria. We report a novel function of CTL1 and CTL2 in ethanolamine transport. Using the lack or the gain of gene function in combination with specific antibodies and transport inhibitors we established two distinct ethanolamine transport systems of a high affinity, mediated by CTL1, and of a low affinity, mediated by CTL2. Both transporters are Na⁺-independent ethanolamine/H⁺ antiporters. Primary human fibroblasts with separate frameshift mutations in the CTL1 gene (M1= SLC44A1^ΔAsp517 and M2= SLC44A1^ΔSer126) are devoid of CTL1 ethanolamine transport but maintain unaffected CTL2 transport. The lack of CTL1 in M2 cells reduced the ethanolamine transport, the flux through the CDP-ethanolamine Kennedy pathway, and PE synthesis. In contrast, overexpression of CTL1 in M2 cells improved ethanolamine transport and PE synthesis. These data firmly establish that CTL1 and CTL2 are the first identified ethanolamine transporters in whole cells and mitochondria, with intrinsic roles in de novo PE synthesis by the Kennedy pathway and intracellular redistribution of ethanolamine.

Ethanolamine: A Potential Promoiety with Additional Effects in the Brain

Ethanolamine is a bioactive molecule found in several cells, including those in the central nervous system (CNS). In the brain, ethanolamine and ethanolamine-related molecules have emerged as prodrug moieties that can promote drug movement across the blood-brain barrier. This improvement in the ability to target drugs to the brain may also mean that in the process ethanolamine concentrations in the brain are increased enough for ethanolamine to exert its own neurological ac-tions. Ethanolamine and its associated products have various positive functions ranging from cell signaling to molecular storage, and alterations in their levels have been linked to neurodegenerative conditions such as Alzheimer's disease. This mini-review focuses on the effects of ethanolamine in the CNS and highlights the possible implications of these effects for drug design.

Ethanolamine Produced from Oleoylethanolamide Degradation Contributes to Acetylcholine/Dopamine Balance Modulating Eating Behavior

Oleoylethanolamide is a well-recognized anorectic compound which also has noteworthy effects on food-reward, influencing the acetylcholine (ACh)/dopamine (DA) balance in the cholinergic system. After its administration, oleoylethanolamide is quickly degraded into oleic acid and ethanolamine. The effect of oleic acid on the gut-brain axis has been extensively investigated, whereas ethanolamine has received scarce attention. However, there is scattered evidence from old and recent research that has underlined the influence of ethanolamine on the cholinergic system. In the present article, we propose a model by which the released ethanolamine contributes to the overall balance between DA and ACh after oleoylethanolamide administration.

Influence of Myo-inositol Plus Ethanolamine on Plasmalogens and Cell Viability during Oxidative Stress

Previously, we demonstrated that treatment of rats with myo-inositol plus ethanolamine (ME) elevated brain ethanolamine plasmalogens (PE-Pls) and protected against phosphine-induced oxidative stress. Here we tested the hypothesis that ME treatment elevates PE-Pls in a neuro-2A (N2A) cell culture system and protects against hydrogen peroxide (H₂O₂)-induced oxidative stress, and we assessed the effects of treatments using myo-inositol with or without (+/-) ethanolamine on ethanolamine phospholipids (PLs) and cell viability following H₂O₂ exposure. Cells were treated with equimolar amounts (500 μM) of myo-inositol, ethanolamine (Etn), or their combination (ME) for 24 h, followed by an additional 24 h exposure to 650 μM H₂O₂. NMR analyses evaluated the treatment effects on Etn PLs, while LC-MS/MS analyses assessed the molecular species of Etn PLs preferentially affected by ME and H₂O₂ treatments, especially PE-Pls and their degradation byproducts-lysophosphatidylethanolamine (LPE) and glycerophosphoethanolamine (GPE). Only ME influenced the cellular levels of PLs. ME yielded a 3-fold increase in PE-Pls and phosphatidylethanolamine (PE) ( p < 0.001) and a preferential 60% increase in PE-Pls containing saturated and monounsaturated fatty acids (SFA+MUFA), while polyunsaturated fatty acid (PUFA) species increased by only 10%. Exposing cells to 650 μM H₂O₂ caused a significant cell death (56% viability), a 27% decrease in PE-Pls, a 201% increase in PUFA-rich LPE, and a ca. 3-fold increase in GPE. H₂O₂ had no impact on PE, suggesting that LPE and GPE were primarily the byproducts of PE-Pls (not PE) degradation. Surprisingly, ME pretreatment ameliorated H₂O₂ effects and significantly increased cell survival to 80% ( p < 0.05). Cellular PE-Pls levels prior to H₂O₂ treatment were highly correlated ( R² = 0.95) with cell survival, suggesting a relationship between PE-Pls and cell protection. Data suggest that a preferential increase in PE-Pls containing SFA+MUFA species may protect cells from oxidative stress. Such studies aid in our understanding of the neuroprotective mechanisms that may be associated with plasmalogens and the relevance of these phospholipids to neurodegenerative diseases/disorders.

Depolarization-induced release of ethanolamine from brain synaptic preparations in vitro

The release of ethanolamine from mouse brain synaptosomes and synaptoneurosomes has been investigated. The depolarizing agents veratridine (50 microM), KCl (35 mM) and 4-aminopyridine (2 mM) enhanced the release of [3H]ethanolamine from preloaded synaptosomes under superfusion conditions. Tetrodotoxin (2 microM) strongly inhibited veratridine- and 4-aminopyridine-stimulated release of [3H]ethanolamine but had no effect on KCl-evoked or resting release. In the absence of calcium, a reduction in the resting release of [3H]ethanolamine occurred and release evoked by veratridine, and KCl was markedly reduced. Exposure of preloaded synaptosomes to 5 mM ethanolamine (but not 5 mM serine or 5 mM choline) calcium-dependently increased the efflux of [3H]ethanolamine, however, this was not accompanied by membrane depolarization. When these experiments were performed using synaptoneurosomes, qualitatively similar results were obtained. The resting and evoked release of [3H]ethanolamine was however approximately 2.5-fold higher compared to synaptosomes on a brain equivalent basis, suggesting that uptake and release occur at sites in addition to the nerve ending. Our data are consistent with the idea that a significant amount of ethanolamine accumulates presynaptically and undergoes calcium-dependent release upon depolarization possibly via classical exocytosis. In contrast, ethanolamine-induced release of [3H]ethanolamine likely involves mostly diffusional exchange across the neuronal membrane rather than base exchange. The present results add support to the concept that ethanolamine may play a role as a synaptic signaling molecule in mammalian brain.

Effects of ethanolamine (Etn) administration on Etn and choline (Ch) levels in plasma, brain extracellular fluid (ECF) and brain tissue, and on brain phospholipid levels in rats: an in vivo study

The sources and fates of brain ethanolamine (Etn) are poorly known and the effects of its administration have not been investigated, even though cortical levels are known to be reduced in certain neurodegenerative diseases. We studied the effect of different Etn doses (10(-3), 5 x 10(-3) and 10(-2) mol/kg, i. p.) on its and choline's (Ch) levels in arterial plasma and brain extracellular fluid (ECF) of awake rats. We also studied its effects on brain levels of Etn, Ch, and their respective major phospholipids. Etn administration caused dose dependent increases in Etn levels within both plasma and brain ECF. For the 10(-2) mol/kg dose, Etn levels were significantly (p<0.01) greater than pre-injection values in both the plasma and ECF. Whole brain Etn and phosphatidylethanolamine were also significantly (p<0.05) increased by 10(-2) mol/kg Etn. Exogenous Etn significantly (p<0.05) increased Ch levels in plasma and whole brain; Etn also increased brain ECF Ch levels. Our data show for the first time that circulating Etn can act as a source of brain Ch. Metabolic pathways that might mediate the increases in Etn and Ch are discussed, as are possible mechanisms of the decreases in brain Eth seen in Alzheimer's disease.

Incorporation of [3H]ethanolamine into acetylcholine by a human cholinergic neuroblastoma clone

Human neuroblastoma cholinergic LA-N-2 cells were used as an experimental model to test the possibility that the methylation of phosphoethanolamine (PEtn) to phosphocholine (PCho) and free choline (Cho) (Andriamampandry et al. 1989) could contribute to acetylcholine (AcCho) synthesis. LA-N-2 cells were incubated with [3H]Cho for 90 min and 22.7% of the radioactivity was present in PCho, 18.5% in free Cho and 4.8% as AcCho. The ratio of Cho/AcCho, however, was of about 1 after 16 hours of incubation. The incorporation of 10 microM [3H]ethanolamine (Etn) into MeEtn, PMeEtn, PMe2Etn and their corresponding phospholipids was reduced in cells incubated in medium containing 7.2 microM choline as compared to cells incubated in medium devoid of choline indicating that the lack of Cho from the incubation medium stimulated the conversion of PEtn to Cho water soluble derivatives. Incubation of LA-N-2 cells with [3H]Etn led to the labelling of [3H]AcCho. Cultures incubated in parallel with [3H]Cho showed that roughly 10% of [3H]AcCho obtained after 16 hrs of incubation with the Cho label derived from [3H]Etn. The synthesis of Cho and AcCho from Etn may be enhanced after cellular differentiation induced by the growth of the cells in the presence of retinoic acid (RA). The results indicate that the methylation of [3H]Etn and/or of [3H]PEtn may be used by cholinergic neurons as precursor for AcCho.

Regulation of ascorbic acid concentration in embryonic chick brain

The relationship between ascorbic acid concentration and cellular transport mechanisms was studied in chicken embryos (Gallus gallus domesticus). Unincubated (Day 0) fertile eggs did not contain detectable levels of ascorbic acid as assayed by high performance liquid chromatography with electrochemical detection. However, ascorbic acid concentration in brain increased to 5.6 nmol/mg tissue by Day 10 in ovo and then gradually declined 32% before birth. These levels were an order of magnitude greater than in skeletal muscle, where ascorbic acid concentration decreased sixfold between Days 8-20. Uptake of ascorbic acid was measured in brain cells that were either freshly isolated or grown in primary culture. Saturable, temperature- and Na(+)-dependent ascorbic acid transport was evident in freshly isolated cells as early as Day 6 and persisted throughout the period of ontogenic development. Primary cultures of embryonic chick brain cells were observed to take up ascorbic acid through a high-affinity (apparent Km = 37 microM, Vmax = 106 nmol ascorbic acid/g protein/min) mechanism. This transport system may maintain the high concentrations of ascorbic acid observed in the central nervous system during the ontogenic period when the levels of ascorbic acid in peripheral tissues change drastically.